In 2010, Bill Gates visited an unremarkable building in an industrial estate on the outskirts of Shenzhen, China. With row after row of high-tech machinery humming inside, the place could easily be mistaken for an anonymous data warehouse.
But Mr Gates and Ray Yip, head of the Gates Foundation’s China operation, saw something else that day. As they toured the BGI headquarters, the two men were stunned by the ambition of the scientists working at the biotech company. Inside, more than 150 state of the art genetic sequencing machines were analysing the equivalent of thousands of human genomes a day.
The company is working towards a goal of building a huge library based on the DNA of many millions of people. BGI executives see this not as the end-game, but as the springboard for new drug discoveries, advanced genetic research and a transformation of public health policy.